Clovis Oncology, Inc. - Common Stock (NQ:CLVS)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 20, 2022 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Clovis Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Crude Oil Down Over 2%; Outset Medical Shares Spike Higher ↗

November 09, 2022

U.S. stocks traded lower midway through trading as investors focused on the outcome of the midterm elections.

Via Benzinga

Clovis Oncology Shares Nose-Dive As Potential Bankruptcy Filing Looms ↗

November 09, 2022

Clovis Oncology Inc (NASDAQ: CLVS) posted a Q3 EPS loss of $(0.39), up from $(0.56) a year ago, on sales of $30.66 million, down from $37.92 million.

Via Benzinga

Rising Incidence of Pancreatic Cancer Driving Demand for Advanced Treatment Therapies

November 07, 2022

Palm Beach, FL – November 7, 2022 – FinancialNewsMedia.com News Commentary – While there is no cure for pancreatic cancer in the pancreatic cancer treatment market, new treatment options abound, and...

Via FinancialNewsMedia

Clovis Oncology's Rubraca Hits Primary Goal In Prostate Cancer Settings ↗

October 03, 2022

Via Benzinga

Why Is Clovis Oncology (CLVS) Stock Up Today? ↗

October 03, 2022

CLVS stock just caught a bid as Clovis advances potential treatment options for men's disease that deserves the medical community's attention.

Via InvestorPlace

What Is Going on With Clovis Oncology (CLVS) Stock Today? ↗

September 13, 2022

Shares of CLVS stock are up more than 25% in the past five days, although August's CPI reading is putting a stop to the rally today.

Via InvestorPlace

Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat

October 27, 2022

From Clovis

Via Business Wire

Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

October 17, 2022

From Clovis

Via Business Wire

What Is Going on With Xperi (XPER) Stock Today? ↗

October 03, 2022

Xperi (XPER) stock is falling on Friday after the media company completed a spinoff of itself from its IP licensing business.

Via InvestorPlace

Why Is Clovis Oncology (CLVS) Stock Up 11% Today? ↗

September 12, 2022

Clovis Oncology (CLVS) stock is rising higher on Monday following the release of results from a Phase 3 ovarian cancer clinical trial.

Via InvestorPlace

Why Is Petrobras (PBR) Stock Up 12% Today? ↗

October 03, 2022

Petrobras (PBR) stock is getting a boost on Monday thanks to a couple of positive bits of news for the Brazilian oil company.

Via InvestorPlace

TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations

October 03, 2022

From Clovis

Via Business Wire

Short Interest Sector Focus: Healthcare Sector ↗

September 26, 2022

As of the close of business on Friday, 9/23, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector...

Via Benzinga

XPEV Stock Alert: 7 Things to Know About the New Xpeng G9 SUV ↗

September 21, 2022

Xpeng (XPEV) stock is on the move Wednesday after the electric vehicle (EV) company revealed its new flagship G9 SUV today.

Via InvestorPlace

What Is Going on With Clovis Oncology (CLVS) Stock Today? ↗

September 21, 2022

Clovis Oncology (CLVS) stock is getting a boost on Wednesday as investors react to news of it reaching a two-year clinical supply agreement.

Via InvestorPlace

Clovis, Isotopia Ink Clinical Supply Pact For Lutetium-177 Used In Its Targeted Cancer Radiation Therapy ↗

September 21, 2022

Via Benzinga

Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement

September 21, 2022

From Clovis Oncology, Inc.

Via Business Wire

Why Virios Therapeutics Is Trading Lower By 75%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session ↗

September 20, 2022

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 51% to $0.4957. Crown ElectroKinetics, last month, posted a Q4 net loss of $4.5 million.

Via Benzinga

Why SOBR Safe Shares Surged Around 233%; Here Are 68 Biggest Movers From Yesterday ↗

September 21, 2022

Gainers

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

September 20, 2022

Good morning, investor! It's time to start the day with a breakdown of the biggest pre-market stock movers for Tuesday morning!

Via InvestorPlace

Why O2Micro International Is Trading Higher By 7%; Here Are 25 Stocks Moving Premarket ↗

September 20, 2022

Gainers

Via Benzinga

Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday ↗

September 13, 2022

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 12, 2022

Via Benzinga

Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday's Mid-Day Session ↗

September 12, 2022

Gainers Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65.

Via Benzinga

Adobe (ADBE) Stock Slips on Analyst Downgrade ↗

September 12, 2022

Adobe (ADBE) stock is sliding lower on Monday after the software company was hit with a downgrade from Mizuho analyst Gregg Moskowitz.

Via InvestorPlace

Clovis Oncology's Flagship Ovarian Cancer Drug Improves Progression-Free Survival As First-Line Maintenance ↗

September 12, 2022

Via Benzinga

Why Is Clovis Oncology Stock Trading Higher Today? ↗

September 12, 2022

Clovis Oncology Inc (NASDAQ: CLVS) shares are trading higher Monday after the company presented data showing Rubraca as a first-line maintenance treatment improved progression-free survival in advanced...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

September 12, 2022

We're starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning and the news moving them.

Via InvestorPlace

Why Clovis Oncology Is Trading Higher By 14%; Here Are 28 Stocks Moving Premarket ↗

September 12, 2022

Gainers Aditxt, Inc. (NASDAQ: ADTX) rose 46.1% to $0.2801 in pre-market trading after jumping 37% on Friday.

Via Benzinga

Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

September 11, 2022

From Clovis Oncology, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.